Table 6.
Clinical characteristics and metabolic profile of GALNT2 rs2144300 genotypes in overweight/obese and non-obese GDM patients.
| Overweight/Obese GDM | Non-obese GDM | |||||
|---|---|---|---|---|---|---|
| CC (226) | CT (97) | TT (7) | CC (82) | CT (45) | TT (4) | |
| Clinical characteristics | ||||||
| Age (years) | 35.23 ± 4.14 | 34.82 ± 4.07 | 36.67 ± 2.65 | 33.56 ± 4.36 | 32.55 ± 4.56 | 37.8 ± 4.27 |
| Gestation age (weeks) | 39.07 ± 0.81 | 38.99 ± 0.91 | 39.42 ± 0.58 | 38.93 ± 1.22 | 39.15 ± 0.71 | 39.10 ± 0.48 |
| Prepregnancy BMI (kg/m2) | 23.36 ± 2.57 | 23.45 ± 3.78 | 22.8 ± 2.08 | 19.28 ± 1.4 | 18.99 ± 1.52 | 19.67 ± 0.95 |
| Weight gain during pregnancy (kg) | 12.17 ± 4.63 | 12.23 ± 4.34 | 12.61 ± 2.23 | 10.64 ± 3.75 | 11.11 ± 3.18 | 10.30 ± 4.44 |
| Delivery BMI (kg/m2) | 28.13 ± 2.33 | 28.61 ± 4.85 | 27.78 ± 2.20 | 23.51 ± 1.09 | 23.34 ± 1.22 | 23.69 ± 1.41 |
| Neonatal birth height (cm) | 49.87 ± 1.79 | 49.68 ± 1.71 | 49.22 ± 1.20 | 48.78 ± 5.7 | 49.22 ± 2.02 | 50.00 ± 3.16 |
| Neonatal birth Weight (g) | 3431.59 ± 448.09 | 3382.73 ± 443.23 | 3301.11 ± 218.48 | 3212.56 ± 547.36 | 3208.44 ± 399.01 | 3662.00 ± 471.18 |
| SBP (mmHg) | 115.98 ± 12.63 | 115.96 ± 10.9 | 114.11 ± 10.65 | 112.58 ± 9.47 | 114.7 ± 9.67 | 119.6 ± 12.36 |
| DBP (mmHg) | 72.57 ± 9.36 | 72.68 ± 9.22 | 73.56 ± 9.32 | 70.98 ± 8.08 | 75.43 ± 9.79a,** | 79.6 ± 7.67b,* |
| Metabolic profile | ||||||
| Fasting Ins (pmol/L) | 90.69 ± 60.64 | 87.03 ± 54.06 | 108.65 ± 60.49 | 66.78 ± 45.05 | 81.46 ± 60.46 | 75.21 ± 54.79 |
| Fasting Glu (mmol/L) | 4.44 ± 1.04 | 4.41 ± 0.77 | 4.46 ± 0.77 | 4.42 ± 0.81 | 4.32 ± 0.87 | 4.42 ± 0.86 |
| HOMA-IR | 4.13 ± 13.51 | 3.69 ± 7.92 | 3.44 ± 2.07 | 2.96 ± 5.09 | 3.01 ± 3.29 | 2.70 ± 2.23 |
| Triglycerides (mmol/L) | 3.94 ± 1.66 | 4.04 ± 1.54 | 3.19 ± 1.22 | 3.9 ± 2.08 | 3.49 ± 1.11 | 3.01 ± 0.78 |
| TC (mmol/L) | 5.88 ± 1.20 | 5.94 ± 1.01 | 5.55 ± 0.97 | 6.38 ± 1.96 | 5.96 ± 0.85 | 5.57 ± 1.32 |
| HDL-C (mmol/L) | 1.97 ± 0.46 | 1.91 ± 0.42 | 1.71 ± 0.33 | 2.08 ± 0.54 | 2.08 ± 0.45 | 1.95 ± 0.68 |
| LDL-C (mmol/L) | 2.93 ± 0.93 | 2.92 ± 0.83 | 2.93 ± 0.81 | 3.09 ± 0.90 | 3.25 ± 1.66 | 2.71 ± 0.65 |
| non-HDLC (mmol/L) | 3.99 ± 1.03 | 4.09 ± 0.91 | 4.29 ± 0.68 | 4.43 ± 1.92 | 3.93 ± 0.88 | 4.05 ± 0.61 |
| Atherogenic index | 2.05 ± 0.60 | 2.23 ± 0.71a,* | 2.60 ± 0.81 | 2.18 ± 0.72 | 1.98 ± 0.70 | 1.88 ± 0.52 |
| TG/HDL-C | 2.05 ± 0.60 | 2.41 ± 1.43 | 2.30 ± 1.18 | 2.18 ± 0.72 | 1.74 ± 0.80 | 1.63 ± 0.50 |
| apoA1(g/L) | 2.28 ± 0.37 | 2.32 ± 0.36 | 2.15 ± 0.34 | 2.32 ± 0.41 | 2.29 ± 0.35 | 2.27 ± 0.42 |
| apoB (g/L) | 1.16 ± 0.28 | 1.18 ± 0.24 | 1.15 ± 0.32 | 1.22 ± 0.26 | 1.16 ± 0.21 | 1.08 ± 0.24 |
| apoB/apoA1 ratio | 0.56 ± 0.14 | 0.56 ± 0.12 | 0.65 ± 0.19 | 0.59 ± 0.14 | 0.54 ± 0.13 | 0.51 ± 0.09 |
a,bcompared with CC genotype carriers in the same group, respectively, *p < 0.05, **p < 0.01.